Revelation Biosciences (REVB) Net Income towards Common Stockholders (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly Net Income towards Common Stockholders of -$2.5 million for Q4 2025, down 45.5% year-over-year from -$4.6 million in Q4 2024, and up 46.31% quarter-over-quarter from -$4.7 million in Q3 2025.
Revelation Biosciences (REVB) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$2.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 45.5% year-over-year to -$2.5 million; the TTM figure through Dec 2025 stood at -$14.9 million (down 4.24% YoY), while the FY2025 annual figure was -$14.9 million, up 1.15% from the prior year.
- Net Income towards Common Stockholders rose to -$2.5 million in Q4 2025 per REVB's latest filing, from -$4.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1853.0 in Q3 2021 and bottomed at -$12.8 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$3.1 million across 5 years, with a median of -$2.0 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 135961.01% — and 2024, when it jumped 86.55%.
- Revelation Biosciences' Net Income towards Common Stockholders stood at $1172.0 in 2021, then plunged by 135961.01% to -$1.6 million in 2022, then sank by 705.75% to -$12.8 million in 2023, then surged by 86.55% to -$1.7 million in 2024, then slumped by 45.5% to -$2.5 million in 2025.
- Business Quant data shows REVB's Net Income towards Common Stockholders at -$2.5 million in Q4 2025, -$4.7 million in Q3 2025, and -$5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | -3.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.32 Mn |
| Dec 31, 2025 | -2.51 Mn |
| Sep 30, 2025 | -4.68 Mn |
| Jun 30, 2025 | -5.63 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Jun 30, 2024 | -8.39 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Dec 31, 2023 | -12.83 Mn |
| Sep 30, 2023 | -2.81 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | -1.71 Mn |
| Dec 31, 2022 | -1.59 Mn |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -1.89 Mn |
| Mar 31, 2022 | -6.64 Mn |
| Dec 31, 2021 | 1,172.00 |
| Sep 30, 2021 | 1,853.00 |
| Jun 30, 2021 | 1,833.00 |